NK-cell activity in immunotoxicity drug evaluation
Related Experiment Video
Updated: Sep 27, 2026

Quantifying NK-Cell Cytotoxicity Potentiated by Chimeric Antigen Receptors and Therapeutic Antibodies Using Live-Cell Imaging and Flow Cytometry
Published on: July 3, 2026
Karin Cederbrant1, Maritha Marcusson-Ståhl, Fabienne Condevaux
1Department of Molecular Toxicology/Immunotoxicology, Safety Assessment, AstraZeneca R&D Södertälje, SE-151 85, Södertälje, Sweden. karin.cederbrant@astrazeneca.com
Abstract:
NK-cell activity as a tool for detection of immunotoxic effects of new human drugs has gained further attention when the recent European note for guidance CPMP/SWP/1042/99 was adopted. The inclusion of NK-cell activity plus distribution of lymphocyte subsets were suggested as an alternative to the primary antibody response to a T-cell dependent antigen. Either of the two test alternatives should be included as a routine parameter in at least one repeated dose-toxicity study, rats or mice being the species of choice. The standard procedure for measuring NK-cell activity is the 51Cr-release assay. However, a new flow-cytometric assay, adapted for rat peripheral blood, does not require dedicated groups of animals, offers the possibility of repeated testing, and shows at least as sensitive as the conventional 51Cr-release assay.

